Literature DB >> 8869119

Dobutamine echocardiography for determining myocardial viability after reperfusion: experimental and clinical observations.

S Kaul1.   

Abstract

Dobutamine echocardiography is being used increasingly to assess the presence of viable myocardium after reperfusion therapy in patients with myocardial infarction. This review places emphasis on results of experimental and pertinent clinical studies in order to provide an understanding of the physiologic basis for using this modality for detecting viable myocardium. It is hoped that an understanding of these principles will allow a more meaningful interpretation of test results in different clinical situations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8869119     DOI: 10.1093/eurheartj/16.suppl_m.17

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

1.  Dobutamine magnetic resonance imaging as a predictor of myocardial functional recovery after revascularisation.

Authors:  R J Trent; G D Waiter; G S Hillis; F I McKiddie; T W Redpath; S Walton
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

2.  Comparison of dobutamine stress echocardiography and exercise stress Thallium-201 SPECT for detection of myocardial ischemia after acute myocardial infarction treated with thrombolysis.

Authors:  M Previtali; G Cannizzaro; L Lanzarini; G Calsamiglia; A Poli; R Fetiveau
Journal:  Int J Card Imaging       Date:  1999-06

3.  Combined assessment of reflow and collateral blood flow by myocardial contrast echocardiography after acute reperfused myocardial infarction.

Authors:  F Leclercq; P Messner-Pellenc; Q Descours; J P Daures; J L Pasquié; F X Hager; J M Davy; R Grolleau-Raoux
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

Review 4.  Assessment of myocardial viability with two-dimensional echocardiography and magnetic resonance imaging.

Authors:  J R Lindner; S Kaul
Journal:  J Nucl Cardiol       Date:  1996 Mar-Apr       Impact factor: 5.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.